News Focus
News Focus
Followers 4
Posts 1330
Boards Moderated 0
Alias Born 01/01/2007

Re: tregaron post# 37717

Monday, 10/17/2011 3:25:25 PM

Monday, October 17, 2011 3:25:25 PM

Post# of 57784
It worries me that you had the same idea. Do you think this would be legal? A CEO of one company sets up another company, sells his company to the new company, and then moves to the new company as CEO. This is sort of like screwing it forward. The fact that Stoll isn't quashing it, and Varney isn't responding gives this thing some credence.
Newman-Tancredi operates out of France, and the only pharma with a stake in corx right now is Servier, which has a bad reputation in france, where they face charges of fraud:
http://www.latribune.fr/entreprises-finance/industrie/chimie-pharmacie/20110926trib000651801/en-attendant-son-proces-servier-rassure-ses-employes-.html

Along with an extensive track-record of hiding dangerous/lethal side effects of their drugs (the attached article translates as "Servier: the shame of french pharma")
http://cpolitic.wordpress.com/2007/11/20/laboratoire-servier-la-honte-de-lindustrie-pharmaceutique-francaise/
the details are pretty hair-raising, particularly a weight-loss drug Isomeride, which caused heart damage.

So Neurolixis may be focusing on delivering corx to Servier, perhaps with Servier's collusion.

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today